Marker Therapeutics(MRKR) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates Preliminary safety and ef icacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin's Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell therapy remains in complete response nine months after MT-601 treatment Company received approval from United States Adopted Name (USAN) council and Internation ...